A recent survey by the New York Thoroughbred Horsemen’s Association (NYTHA) revealed that most trainers and owners would likely reduce their race participation if the current race-day ban on the anti-bleeding medication furosemide (Lasix) were extended to all races for horses aged three and older. The survey found that 81% of respondents would race less under a full ban, and 80% have already chosen races based on the ability to use Lasix. The medication, used since 1974 to mitigate exercise-induced pulmonary hemorrhaging (EIPH), is currently banned on race day only for 2-year-olds and stakes races, with a three-year exemption for other races set to expire in May 2026.

HISA funded three studies examining the effects of furosemide on horse health, performance, and career longevity, with results submitted in January. Survey responses indicated mixed observations on EIPH severity in 2-year-olds and varied retirement rates due to EIPH-related conditions. The research aims to clarify the impact of furosemide use and the consequences of its potential ban, informing HISA’s upcoming decision on race-day medication policies.